Abeona Therapeutics (ABEO) EBT (2011 - 2026)

Abeona Therapeutics' EBT history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• On a quarterly basis, EBT fell 41.93% year-over-year to -$17.1 million in Q1 2026; TTM through Mar 2026 was $66.2 million, a 249.91% increase from a year earlier, with the FY2025 full-year figure at $71.3 million, up 211.84% from the prior year.
• EBT rose to -$17.1 million in Q1 2026 per ABEO's latest filing, from -$20.7 million in the prior quarter.
• Across five years, EBT topped out at $124.3 million in Q2 2025 and bottomed at -$32.1 million in Q1 2022.
• The 5-year median for EBT is -$13.3 million (2023), against an average of -$7.5 million.
• Across the five-year window, EBT plunged 138.26% in 2024 and soared 1578.98% in 2025, its largest moves.
• Year by year, EBT stood at -$13.1 million in 2022, then declined by 1.56% to -$13.3 million in 2023, then jumped by 30.22% to -$9.3 million in 2024, then slumped by 122.48% to -$20.7 million in 2025, then increased by 17.42% to -$17.1 million in 2026.
• Per Business Quant, the three latest ABEO EBT figures stand at -$17.1 million (Q1 2026), -$20.7 million (Q4 2025), and -$20.4 million (Q3 2025).